Abbott Laboratories
ABT
$106.64
-$0.255-0.24%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 1.59B | 1.44B | 1.38B | 1.32B | 1.03B |
| Total Depreciation and Amortization | 813.00M | 824.00M | 800.00M | 806.00M | 807.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 240.00M | 117.00M | 132.00M | 281.00M | 330.00M |
| Change in Net Operating Assets | 391.00M | -500.00M | -1.10B | -1.26B | 156.00M |
| Cash from Operations | 3.04B | 1.88B | 1.20B | 1.14B | 2.33B |
| Capital Expenditure | -755.00M | -560.00M | -507.00M | -380.00M | -610.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -51.00M | -826.00M | -- | -- |
| Divestitures | 0.00 | 0.00 | 40.00M | -- | 0.00 |
| Other Investing Activities | -69.00M | -23.00M | 80.00M | -82.00M | -22.00M |
| Cash from Investing | -824.00M | -634.00M | -1.21B | -462.00M | -632.00M |
| Total Debt Issued | 22.00M | 0.00 | 1.00M | -- | 10.00M |
| Total Debt Repaid | -961.00M | -1.51B | 11.00M | -42.00M | 0.00 |
| Issuance of Common Stock | 34.00M | 56.00M | 15.00M | 62.00M | 41.00M |
| Repurchase of Common Stock | -259.00M | -2.00M | -426.00M | -540.00M | -685.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -888.00M | -888.00M | -890.00M | -890.00M | -823.00M |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.05B | -2.34B | -1.29B | -1.41B | -1.46B |
| Foreign Exchange rate Adjustments | 25.00M | -29.00M | -27.00M | 8.00M | 51.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 187.00M | -1.13B | -1.33B | -721.00M | 288.00M |
